1077 related articles for article (PubMed ID: 29936695)
21. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
22. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Jablonska PA; Diez-Valle R; Pérez-Larraya JG; Moreno-Jiménez M; Idoate MÁ; Arbea L; Tejada S; Garcia de Eulate MR; Ramos L; Arbizu J; Domínguez P; Aristu JJ
PLoS One; 2019; 14(6):e0217881. PubMed ID: 31170245
[TBL] [Abstract][Full Text] [Related]
23. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial.
Izzuddeen Y; Gupta S; Haresh KP; Sharma D; Giridhar P; Rath GK
J Neurooncol; 2020 Jan; 146(1):91-95. PubMed ID: 31728883
[TBL] [Abstract][Full Text] [Related]
25. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Minniti G; De Sanctis V; Muni R; Rasio D; Lanzetta G; Bozzao A; Osti MF; Salvati M; Valeriani M; Cantore GP; Maurizi Enrici R
J Neurooncol; 2009 Jan; 91(1):95-100. PubMed ID: 18758912
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
[TBL] [Abstract][Full Text] [Related]
29. Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
Chen L; Guerrero-Cazares H; Ye X; Ford E; McNutt T; Kleinberg L; Lim M; Chaichana K; Quinones-Hinojosa A; Redmond K
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):616-22. PubMed ID: 23540348
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.
Donato V; Papaleo A; Castrichino A; Banelli E; Giangaspero F; Salvati M; Delfini R
Tumori; 2007; 93(3):248-56. PubMed ID: 17679459
[TBL] [Abstract][Full Text] [Related]
31. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.
Uto M; Mizowaki T; Ogura K; Arakawa Y; Mineharu Y; Miyamoto S; Hiraoka M
Int J Clin Oncol; 2016 Dec; 21(6):1023-1029. PubMed ID: 27384182
[TBL] [Abstract][Full Text] [Related]
32. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
34. Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Guckenberger M; Mayer M; Buttmann M; Vince GH; Sweeney RA; Flentje M
Strahlenther Onkol; 2011 Sep; 187(9):548-54. PubMed ID: 21858417
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y;
BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402
[TBL] [Abstract][Full Text] [Related]
36. Extent of surgical resection and adjuvant temozolomide improves survival in pediatric GBM: a single center experience.
Gupta S; Mallick S; Benson R; Haresh KP; Julka PK; Rath GK
Childs Nerv Syst; 2017 Jun; 33(6):951-956. PubMed ID: 28424876
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
38. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
39. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Stupp R; Mason WP; van den Bent MJ; Weller M; Fisher B; Taphoorn MJ; Belanger K; Brandes AA; Marosi C; Bogdahn U; Curschmann J; Janzer RC; Ludwin SK; Gorlia T; Allgeier A; Lacombe D; Cairncross JG; Eisenhauer E; Mirimanoff RO; ;
N Engl J Med; 2005 Mar; 352(10):987-96. PubMed ID: 15758009
[TBL] [Abstract][Full Text] [Related]
40. Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
Chidley P; Shanker M; Phillips C; Haghighi N; Pinkham MB; Whittle JR; Sia J
J Neurooncol; 2022 Nov; 160(2):361-374. PubMed ID: 36355260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
